The National Cancer Institute (NCI), part of the National Institutes of Health, is the lead federal agency for cancer research. For more information about NCI, visit us at www.cancer.gov. Privacy policy: https://www.cancer.gov/policies/privacy-security Engagement ≠ endorsement
New Product & Tech activity — 2 fresh signals just appeared.
The order this company entered each market — oldest to newest
Ascentage Presents Olverembatinib Data at ASCO
Ascentage Pharma Presents Olverembatinib Data at ASCO
Sign up to see the full signal feed
How National Cancer Institute (NCI)'s international expansion compares to its competitors
National Cancer Institute (NCI)YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 National Cancer Institute (NCI)You | 2 | 2 | +100% | 3 | 16 |
Communications Specialist
View postingWashington DC-Baltimore Area · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Ascentage Pharma presented data on APG-2575 for CLL/SLL treatment at ASH 2024, showing strong efficacy and safety profile in single and combination therapies.
Ascentage Pharma presented clinical data on APG-2575 for R/R MM at ASH, showing strong efficacy and safety in combination therapy.
Tech giants endorse tripling nuclear energy capacity by 2050, driven by AI's energy demands and strategic interests, despite historical risks and public concerns.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about National Cancer Institute (NCI)'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
